���发背景与监管地位 — Explained

By Editorial Desk · published 2025-10-05 · last reviewed 2025-11-15 · Blog

The short version of ACTH 片段 fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-11-15 and is reviewed periodically as new material appears.

研发背景与监管地位

Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。

各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。

Chemical Identity and Research Background

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.

Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.

Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.

Semax at a glance

Semax Background and Molecular Structure

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.

The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.

Related pages on this site

• Professional report
• Clear checklist
• Seasonal reference
• Automated review
• Balanced index
• Durable review
• Durable handbook
• Adaptive review

Semax Origin and Molecular Structure

Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.

Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.

Background from the literature

=== Liver === The human liver is particularly known for its ability to regenerate, and is capable of doing so from only one quarter of its tissue, due chiefly to the unipotency of hepatocytes. Resection of liver can induce the proliferation of the remaining hepatocytes until the lost mass is restored, where the intensity of the liver's response is directly proportional to the mass resected. For almost 80 years surgical resection of the liver in rodents has been a very useful model to the study of cell proliferation.

== Awards == Twin Peaks won a 2010 Hot Concept award from Nation's Restaurant News. In 2011, Twin Peaks was named "Franchisee of the Year" by the International Franchise Association at their annual conference in Washington, D.C. Twin Peaks was named number 1 in Knapp Track for comp sales in 2017 among all casual dining brands. In 2017, Twin Peaks was named a winner in the Enterprise Innovator category at the 2017 MURTEC (Multi-Unit Restaurant Technology Conference). In 2018, Twin Peaks was ranked number 196 on the Franchise Times top 200 list.

=== Early knowledge and study === Humans have had an observational relationship with birds since prehistory, with some stone-age drawings being amongst the oldest indications of an interest in birds. Birds were perhaps important as food sources, and bones of as many as 80 species have been found in excavations of early Stone Age settlements. Water bird and seabird remains have also been found in shell mounds on the island of Oronsay off the coast of Scotland.

Sources: en.wikipedia.org

Further detail

In 2000, Guinness's 1999 advertisement Surfer was named the best television commercial of all time, in a UK poll conducted by The Sunday Times and Channel 4. This advertisement is inspired by the famous 1980s Guinness TV and cinema ad, Big Wave, centred on a surfer riding a wave while a bikini-clad sunbather takes photographs. The 1980s advertisement not only remained a popular iconic image in its own right; it also entered the Irish cultural memory through inspiring a well-known line in Christy Moore's song "Delirium Tremens" (1985). Surfer was produced by the advertising agency Abbott Mead Vickers BBDO; the advertisement can be downloaded from their website. Guinness won the 2001 Clio Award as the Advertiser of the Year, citing the work of five separate ad agencies around the world. In 2002, Guinness applied the Michael Power formula to Asia with the character Adam King. The campaign featured such tag lines as: "Everyday someone, somewhere achieves something new. Sometimes on a grand, dramatic scale. Sometimes on a more personal scale." As of 2004, Guinness ranked among the top three beer labels in Singapore and Malaysia, with a 20 per cent market share across Southeast Asia. Malaysia was the brand's third-largest market in the region and the sixth largest market worldwide. In 2003, the Guinness TV campaign featuring Tom Crean won the gold Shark Award at the International Advertising Festival of Ireland, while in 2005 their Irish Christmas campaign won a silver Shark.

Through the early stages of the game, Combine Civil Protection units pursue Gordon Freeman, the player character, through City 17 after Gordon's presence is mistakenly revealed to Dr. Breen. Due to Gordon's actions in Half-Life and his subsequent disappearance, which earned him a legendary reputation, Dr. Breen sees Gordon as a significant threat. As Gordon flees the city, Civil Protection units raid the resistance base of Black Mesa East and capture resistance leader Eli Vance, who is transferred to holding facilities at Nova Prospekt. Gordon, along with Eli's daughter Alyx, breaks into the facility to rescue him, but Eli is teleported to the Combine Citadel by double agent Judith Mossman. The strike against Nova Prospekt prompts a revolution by the citizens of Earth and heavy street fighting takes place. In Episode One, the destruction of the teleporter has isolated Combine forces on Earth, and its primary reactor has begun to melt down. This forces Gordon and Alyx to journey back into the critically damaged Citadel to stabilize its reactor while the city's inhabitants are evacuated. The Combine forces, however, instead attempt to accelerate the meltdown in order to contact their native dimension for reinforcements. After Alyx acquires an encrypted copy of the message to be sent, Overwatch forces desperately attempt to stop the pair from escaping the city, spurred on by Combine Advisors. As the pair escape on a train at the end of the game, the Citadel detonates and destroys City 17.

Prolactin-releasing hormone, also known as PRLH, is a hypothetical human hormone or hormone releasing factor. Existence of this factor has been hypothesized as prolactin is the only currently known hormone for which almost exclusively negative regulating factors are known (such as dopamine, leukemia inhibitory factor, some prostaglandins) but few stimulating factor. Its secretion is mediated by estrogen from placenta during pregnancy to elevate blood level of prolactin. While many prolactin stimulating and enhancing factors are well known (such as thyrotropin-releasing hormone, oxytocin, vasoactive intestinal peptide and estrogen) those have primary functions other than stimulating prolactin release and the search for hypothetical releasing factor or factors continues. The prolactin-releasing peptide identified in 1998 was a candidate for this function, however as of 2008 it appears its function is not yet completely elucidated.

Sources: en.wikipedia.org

Frequently asked questions